China

China has become a CEO-level priority for multinational pharmaceutical companies: the trend and the implications
China has become a CEO-level priority for multinational pharmaceutical companies: the trend and the implications
Endpoints
China
pharma industry
Flag link:
These 7 trends matter the most for medtech in 2019
These 7 trends matter the most for medtech in 2019
Mass Device
China
robotic surgery
devices
Stryker
Medtronic
FDA
Intuitive Surgical
Flag link:
AstraZeneca raises sales forecast after second-quarter cancer drug, China boost
AstraZeneca raises sales forecast after second-quarter cancer drug, China boost
Yahoo/Reuters
AstraZeneca
earnings
China
Flag link:
Novartis multiple sclerosis product Gilenya approved in China
Novartis multiple sclerosis product Gilenya approved in China
Pharmaceutical Business Review
China
Novartis
multiple sclerosis
Gilenya
Flag link:
HitGen joins growing Shanghai IPO queue
HitGen joins growing Shanghai IPO queue
BioCentury
HitGen
IPOs
China
Shanghai
Flag link:
Megadeals Enter Biotech Realm — And 3 Other Trends To Watch In 2019
Megadeals Enter Biotech Realm — And 3 Other Trends To Watch In 2019
Investors Business Daily
biotech
M&A
China
Flag link:
Trade tensions are impeding the flow of Chinese money to US biotechs — but how much?
Trade tensions are impeding the flow of Chinese money to US biotechs — but how much?
Endpoints
China
venture capital
biotech
trade
Flag link:
Zai builds cancer combo strategy with rights to Incyte's PD-1 mAb
Zai builds cancer combo strategy with rights to Incyte's PD-1 mAb
BioCentury
Zai Lab
China
PD-1 inhibitors
Incyte
Flag link:
Another Biotech Plant Explosion in China Kills Six
Another Biotech Plant Explosion in China Kills Six
BioSpace
China
drug manufacturing
Flag link:
Copycats wanted: Pfizer, AZ and more under threat as China solicits generics
Copycats wanted: Pfizer, AZ and more under threat as China solicits generics
Fierce Pharma
FDA
patents
generics
copycat drugs
China
Flag link:
June 14 P&P Quick Takes: Washington state approved for subscription HCV model; plus Merck and IBM, BGI, and more
June 14 P&P Quick Takes: Washington state approved for subscription HCV model; plus Merck and IBM, BGI, and more
BioCentury
Washington
Netflix model
hepatitis C
BGI Genomics
China
distribution
Flag link:
Tessa Therapeutics Forges $120 Million Joint Venture to Develop Cell Therapies in China
Tessa Therapeutics Forges $120 Million Joint Venture to Develop Cell Therapies in China
BioSpace
Tessa Therapeutics
cell therapy
cancer
China-Singapore Guangzhou Knowledge City
China
Flag link:
Eli Lilly, BMS among 77 drugmakers targeted in Chinese financial probe
Eli Lilly, BMS among 77 drugmakers targeted in Chinese financial probe
Fierce Pharma
China
Sanofi
Eli Lilly
Bristol-Myers Squibb
Flag link:
Fast moving Chinese regulators wave third homegrown PD-1 to market
Fast moving Chinese regulators wave third homegrown PD-1 to market
Endpoints
China
Jiangsu Hengrui Medicine
PD-1 inhibitors
Flag link:
China's driving sales growth ahead of the U.S. for Big Pharma. But can it last?
China's driving sales growth ahead of the U.S. for Big Pharma. But can it last?
Fierce Pharma
China
Big Pharma
Flag link:
US Crackdown On Foreign Biotech Investment Makes Us Poorer, Not Safer
US Crackdown On Foreign Biotech Investment Makes Us Poorer, Not Safer
Forbes
biotech
international investment
China
Flag link:
GlaxoSmithKline's booming Shingrix, after VIP invite, wins nod to tackle China
GlaxoSmithKline's booming Shingrix, after VIP invite, wins nod to tackle China
Fierce Pharma
GSK
vaccines
Shingrix
shingles
China
Flag link:
[video]Top vaccine makers Merck and Pfizer target China and older adults next
[video]Top vaccine makers Merck and Pfizer target China and older adults next
Yahoo/CNBC
vaccines
Merck
Pfizer
Sanofi Pasteur
GSK
China
Flag link:
With potential launches nearing, Zai taps investors for $200M
With potential launches nearing, Zai taps investors for $200M
BioCentury
Zai Lab
China
drug launches
Flag link:
Soriot sees progress in U.S.-China IP debate
Soriot sees progress in U.S.-China IP debate
BioCentury
China
AstraZeneca
Pascal Soriot
intellectual property
Flag link:

Pages